Back To The Drawing Board: Which Drugs Received Complete Response Letters From The FDA In July?

The biotechnology sector is a high-risk investment arena, and investing in these companies requires considerable patience. Drug developers can spend years - even decades - and billions of dollars bringing a new therapy to market.